Cargando…

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomized trial

BACKGROUND: Baricitinib is an oral, selective, reversible Janus kinase 1/2 inhibitor approved in the European Union and Japan and under investigation in the United States for treatment of atopic dermatitis (AD). OBJECTIVES: To evaluate the impact of baricitinib plus background topical corticosteroid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wollenberg, A., Nakahara, T., Maari, C., Peris, K., Lio, P., Augustin, M., Silverberg, J.I., Rueda, M.J., DeLozier, A.M., Pierce, E., Yang, F.E., Sun, L., Ball, S., Tauber, M., Paul, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Allergy and Eczema
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251919/ https://www.ncbi.nlm.nih.gov/pubmed/33834521 http://dx.doi.org/10.1111/jdv.17278

Ejemplares similares

Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients
por: Roekevisch, E., et al.
Publicado: (2020)

Validation of the Patient‐Oriented SCORing for Atopic Dermatitis tool for black skin
por: Faye, O., et al.
Publicado: (2019)

Both children and adult patients with difficult‐to‐treat atopic dermatitis have high prevalences of concomitant allergic contact dermatitis and are frequently polysensitized
por: Boonstra, M., et al.
Publicado: (2018)

Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis: an analysis of patient‐reported outcomes
por: Cork, M.J., et al.
Publicado: (2021)

The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
por: de Bruin‐Weller, M., et al.
Publicado: (2020)

The current extent of and need for shared decision making in atopic dermatitis and psoriasis in the Netherlands: an online survey study amongst patients and physicians
por: van der Kraaij, G.E., et al.
Publicado: (2020)

Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis
por: Thyssen, J.P., et al.
Publicado: (2021)

Stepwise approach of development of dermo‐cosmetic products in healthy and atopic dermatitis paediatric population: safety evaluation, clinical development and postmarket surveillance
por: Ribet, V., et al.
Publicado: (2019)

A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy
por: Paller, A.S., et al.
Publicado: (2020)

Defining and measuring ‘eczema control’: an international qualitative study to explore the views of those living with and treating atopic eczema
por: Howells, L., et al.
Publicado: (2019)

Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7
por: Thyssen, Jacob P., et al.
Publicado: (2021)

A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real‐world study in Belgium
por: Lapeere, H., et al.
Publicado: (2019)

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Reich, Kristian, et al.
Publicado: (2020)

Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Allergen‐specific immunotherapy with apples: selected cultivars could be a promising tool for birch pollen allergy
por: Nothegger, B., et al.
Publicado: (2020)

Asthma improvement in patients treated with dupilumab for severe atopic dermatitis
por: Dubini, Marco, et al.
Publicado: (2023)

Proteomics Profiling to Distinguish DOCK8 Deficiency From Atopic Dermatitis
por: Jacob, Minnie, et al.
Publicado: (2021)

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis
por: Simpson, Eric L., et al.
Publicado: (2022)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Obesity and the microbiome in atopic dermatitis: Therapeutic implications for PPAR-γ agonists
por: McAleer, Jeremy P.
Publicado: (2023)

Survey of topical exposure concerns for patients and caregivers dealing with atopic dermatitis
por: Ratley, Grace, et al.
Publicado: (2023)

Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Navigating patients with atopic dermatitis or chronic spontaneous urticaria during the COVID-19 pandemic
por: Haddad, Isabelle, et al.
Publicado: (2022)

Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
por: King, Brett, et al.
Publicado: (2021)

Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience
por: ROGNER, Danielle, et al.
Publicado: (2022)

Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
por: WOLLENBERG, Andreas, et al.
Publicado: (2022)

The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials
por: Yosipovitch, Gil, et al.
Publicado: (2022)

339 Sensitization to Contactants in Patients with Atopic Dermatitis
por: Matsumoto, Fausto, et al.
Publicado: (2012)

Emollient efficacy and acceptability in the treatment of eczematous dry skin: A double-blind, randomised comparison of two UK-marketed products
por: Djokic-Gallagher, Jasmina, et al.
Publicado: (2016)

Burden of chronic urticaria relative to psoriasis in five European countries
por: Balp, M.M., et al.
Publicado: (2017)

Atopic Dermatitis: Beyond the Skin and Into the Gut
por: Sadowsky, Rachel L., et al.
Publicado: (2023)

Associations between atopic dermatitis and other disorders
por: Silverberg, Jonathan I.
Publicado: (2018)

Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need
por: Pereira, M.P., et al.
Publicado: (2018)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Baricitinib Lipid-Based Nanosystems as a Topical Alternative for Atopic Dermatitis Treatment
por: Garrós, Núria, et al.
Publicado: (2023)

Relations between a standardized experimental stressor and cutaneous sensory function in patients with chronic pruritus and healthy controls: an experimental case–control study
por: Schneider, G., et al.
Publicado: (2018)

Atopic dermatitis
por: Werfel, Thomas
Publicado: (2011)

Atopic dermatitis
por: Watson, Wade, et al.
Publicado: (2011)

Atopic dermatitis
por: Kapur, Sandeep, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j446t8am9rusmntd19esgalfi2